Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$7.12 - $20.24 $1.57 Million - $4.45 Million
220,012 Added 13.37%
1,865,281 $37.2 Million
Q2 2022

Aug 12, 2022

SELL
$5.1 - $10.0 $3.13 Million - $6.13 Million
-613,487 Reduced 27.16%
1,645,269 $11.3 Million
Q1 2022

May 13, 2022

SELL
$8.34 - $14.69 $5.02 Million - $8.84 Million
-601,897 Reduced 21.04%
2,258,756 $21 Million
Q4 2021

Feb 14, 2022

BUY
$13.6 - $24.89 $921,468 - $1.69 Million
67,755 Added 2.43%
2,860,653 $40.7 Million
Q3 2021

Nov 12, 2021

BUY
$21.22 - $25.7 $10.5 Million - $12.8 Million
497,048 Added 21.65%
2,792,898 $64.8 Million
Q2 2021

Aug 13, 2021

BUY
$22.86 - $30.95 $52.5 Million - $71.1 Million
2,295,850 New
2,295,850 $57.1 Million

Others Institutions Holding FMTX

About Forma Therapeutics Holdings, Inc.


  • Ticker FMTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,860,400
  • Market Cap $958M
  • Description
  • Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobin...
More about FMTX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.